Kyle Gano, Chief Business Development Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 2,704 shares at $132.89 ($359K) on 2024-02-13, disclosed to the SEC on 2024-02-15.
Scheduled sale ($359k) by Chief Business Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $132.89 | 1,352 | $180K | 50.0% |
| 2 | $132.89 | 1,352 | $180K | 50.0% |
| Total | $132.89 avg | 2,704 | $359K | 100% |
| Filing → |
| NBIX | SELL | 2025-02-14 | $598K | — | Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $471K | — | Filing → |